Alto Neuroscience Future Growth
Future criteria checks 0/6
Alto Neuroscience's earnings are forecast to decline at 19.2% per annum while its annual revenue is expected to grow at 75.9% per year. EPS is expected to grow by 18% per annum.
Key information
-19.2%
Earnings growth rate
18.0%
EPS growth rate
Pharmaceuticals earnings growth | 23.7% |
Revenue growth rate | 75.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 23 Apr 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -137 | -91 | -144 | 4 |
12/31/2025 | N/A | -81 | -74 | -86 | 5 |
12/31/2024 | N/A | -57 | -56 | -59 | 5 |
12/31/2023 | N/A | -36 | -34 | -33 | N/A |
9/30/2023 | N/A | -33 | -28 | -28 | N/A |
12/31/2022 | N/A | -28 | -21 | -20 | N/A |
12/31/2021 | 0 | -9 | -10 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ANRO is forecast to have no revenue next year.
High Growth Revenue: ANRO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANRO's Return on Equity is forecast to be high in 3 years time